Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a multi-drug combination therapy consisting of: - **Cefoperazone** (a third-generation cephalosporin antibiotic) and **Sulbactam** (a beta-lactamase inhibitor), which together provide broad-spectrum antibacterial activity, especially against resistant Gram-negative and some Gram-positive bacteria. Sulbactam protects cefoperazone from degradation by beta-lactamases, enhancing its efficacy. - **Ursodeoxycholic acid**, a bile acid used to improve bile flow and treat cholestatic liver diseases. - **Compound glycyrrhizin**, derived from licorice root, with anti-inflammatory and hepatoprotective properties. - **Methylprednisolone**, a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive effects. - Fat-soluble vitamins (**A, D, E, K**) for nutritional support or correction of deficiencies; these are essential for vision, bone health, antioxidant protection, and coagulation respectively. - Two carbapenem antibiotics (**Imipenem** and **Meropenem**) that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins; both are highly effective against multidrug-resistant organisms. This combination would be used in complex clinical scenarios such as severe infections (including those caused by multidrug-resistant organisms), often in patients with compromised liver function or requiring intensive supportive care. The inclusion of hepatoprotective agents (ursodeoxycholic acid/glycyrrhizin) alongside broad-spectrum antibiotics suggests use in patients at risk for hepatic injury or dysfunction. Methylprednisolone provides additional anti-inflammatory action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefoperazone + sulbactam + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin A + vitamin D + vitamin E + vitamin K + imipenem + meropenem.